

Laurus Labs
TRACK RECORD



Laurus Labs
TRACK RECORD

8 Change, if any, in directors of issuer from the disclosures in the offer document
(i) at the end of 1st FY (During FY17)

Names of directors

Mr. Amal Ganguli
Mr. Frank J Wright
Conner Town Mulvee
Ravindranath Kancherla

Details of Change

Resigned
Resigned
Resigned

(ii) at the end of 2nd FY (During FY18)

Names of directors

Rajesh Dugar
Dr. Srihari Raju Kalidindi
Dr. Venkata Lakshmana Rao Chunduru

Details of Change

Resigned
Resigned
Appointment

(iii) at the end of 3rd FY (During FY19)

Names of directors

Venu Gopala Rao

Details of Change

Appointment

Note: Change in Directors not disclosed as the relevant fiscal years have not been completed.

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document

Not Applicable

(ii) Actual implementation

Not Applicable

(iii) Reasons for delay in implementation, if any

Not Applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

Particulars	Total Estimated Fund Requirement (Rs cr)	Fiscal 2017 (Rs cr)	Fiscal 2018 (Rs cr)	Fiscal 2019 (Rs cr)
Pre-payment of term loans	226.29	226.29	-	-
General Corporate Purposes	60.42	60.42	-	-

Notes: (1) As disclosed in the Prospectus

(ii) Actual utilization

Particulars	Total Estimated Fund Requirement (Rs cr)	Utilization in fiscal 2017 (Rs cr)	Utilization in fiscal 2018 (Rs cr)	Utilization in fiscal 2019 (Rs cr)
Pre-payment of term loans	226.29	226.29	-	-
General Corporate Purposes	60.42	60.42	-	-

(iii) Reasons for deviation, if any

NA

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds

NA

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document

NA

(c) Any other reservations expressed by the monitoring agency about the end use of funds

NA

Laurus Labs
TRACK RECORD

12 Price-related data

Issue price: INR428/unit

Price parameters	At close of listing day (19 Dec 2017)	At close of 30th calendar day from listing day (18 Jan 2016)	At close of 90th calendar day from listing day (17 March 2017)	As at the end of FY207			As at the end of FY2018 ⁽³⁾			As at the end of FY2019 ⁽³⁾		
				Closing price (31 March 2018)	High (during the FY)	Low (during the FY)	Closing price (29 Mar 2019)	High (during the FY)	Low (during the FY)	Closing price (31 Mar 2020)	High (during the FY)	Low (during the FY)
Market Price ⁽¹⁾	480.40	478.10	530.60	516.20	559.85	455.20	502.85	628.40	502.20	399.50	520.00	321.40
Index (CNX Nifty) ⁽²⁾	8,104.35	8,417.00	9,160.05	9,173.75	9,173.75	30,680.66	10,113.70	11,130.40	9,103.50	11,623.90	11,760.20	10,004.50

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	As disclosed in offer document*	At the end of 1st FY (March 31,2017)**	At the end of 2nd FY (March 31,2018)**	At the end of 3rd FY (March 31,2019)**
EPS (Basic)	Issuer:	20.86	18.79	15.83	8.83
	Peer Group ⁽⁴⁾:	37.81	34.42	37.2	45.66
P/E	Issuer:	20.52	27.47	31.77	45.27
	Peer Group ⁽⁴⁾:	26.03	22.93	23.24	26.45
RoNW	Issuer:	15.57%	14.30%	11.30%	5.97%
	Peer Group ⁽⁴⁾:	30.37%	19.85%	17.77%	18.23%
NAV per share	Issuer:	135.06	125.8	139.83	146.28
	Peer Group ⁽⁴⁾:	141.56	173.87	211.28	249.56

Notes

* Sourced and caculated as per Prospectus dated December 12, 2016 and Company filings uploaded on the stock exchange websites

** Peer groups include Divis Laboratories Ltd. amd Aurobindo Pharma Limited

***Not available as the relevant fiscal years have not been completed

Laurus Labs
TRACK RECORD

14 Any other material information

Laurus Labs Ltd has informed BSE that consequent to listing of equity shares of the Company on the Stock Exchanges,

Laurus Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 09, 2017, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter and 9 months period ended December 31, 2016. Further, the Company's trading window for dealing in securities by the Directors and Designated Persons shall be closed from February 03, 2017 to February 11, 2017 (both days inclusive)

Mr. Frank J Wright (DIN 01609467), the Director of the Company, has tendered his resignation from the Board of the Company with effect from March 31, 2017. A copy of the said resignation letter received by the Company is attached for your information and records

26/Mar/19: Laurus Labs enters into strategic partnership agreement with the Global Fund

All the above information is updated till Nov 11, 2020, unless indicated otherwise



DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the "Circular") for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

Laurus Labs
TRACK RECORD

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as “www.capitalmarkets.com” and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of Nov 11, 2020. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.